Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients wit
- PDF / 905,599 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 181 Views
(2020) 17:74
RESEARCH
Open Access
Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial Saber Jafari-Maskouni1, Mansour Shahraki1*, Milad Daneshi-Maskooni2* , Alireza Dashipour3, Ali Shamsi-Goushki1 and Zinat Mortazavi1
Abstract Background: Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the metabolic and clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with T2DM. Methods: Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Due to the eligibility criteria, 60 participants were randomly placed into two groups, namely placebo (n = 30) and BP (n = 30). The supplementation was considered one 1000 mg capsule 2 times /day BP by meals (lunch and dinner) for 8 weeks. Physical activity levels, dietary intakes, anthropometric measurements [weight, height, and waist circumference], glycemic indices [fasting blood glucose (FBG) and insulin (FBI)], blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)], and serum nesfatin-1 level were determined. Homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative insulin sensitivity checks index (QUICKI), and Body Mass Index (BMI) were computed. Results: In comparison with placebo, BP significantly decreased FBG, HOMA-IR, and BMI (P < 0.05). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (P > 0.05). Conclusion: BP supplementation improved serum glucose indices and BMI among overweight and obese T2DM patients. Further trials are needed to confirm results. Trial registration: Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https://irct.ir/ trial/35752 Keywords: Type 2 diabetes, Bunium Persicum, Glucose indices, Lipids, Nesfatin-1
* Correspondence: [email protected]; [email protected] 1 Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran 2 Department of Nutrition, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by
Data Loading...
